A Study of TH-SC01 for Treating Complex Perianal Fistula in Perianal Crohn's Disease.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-11-12

Study Completion Date

2024-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to asses the efficacy and Safety of Allogeneic Umbilical Cord-derived Mesenchymal Stem Cells in the Treatment of Complex Perianal Fistula in Perianal Crohn's Disease.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease

NCT05626023

Perianal Fistula Crohn's Disease

COMPLETED PHASE1/PHASE2

Safety of Allogeneic Human Umbilical Cord Mesenchymal Stem Cells (UC-MSCs) to Treat Perianal Fistulas w/ Crohn's Disease

NCT05039411

Perianal Fistula Due to Crohn's Disease Fistula in Ano

RECRUITING PHASE1

Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells in the Treatment of Moderate and Severe Crohn's Disease

NCT05262829

Crohn Disease

UNKNOWN NA

Phase 3 Study of Human TH-SC01 Cell Injection for Treating Perianal Fistulas in Patients With Crohn's Disease

NCT06925594

Crohn's Disease

RECRUITING PHASE3

Mesenchymal Stem Cells for the Treatment of Perianal Fistulizing Crohn's Disease

NCT04519671

Perianal Crohn Disease Perianal Fistula Crohn Disease

UNKNOWN PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Crohn´s disease (CD) can affect any part of the digestive system and symptoms of this chronic illness include abdominal pain, bloating, nausea, vomiting and diarrhea. CD also causes bowel wall ulcers, strictures and fistulas (abnormal passages from the intestines to another organ or the skin).

There is an unmet need for effective medical therapy in CD patients with perianal fistulas, not responding to the conventional strategies, including biological therapies. The current study is designed to assess the safety and efficacy of Allogeneic Umbilical Cord-derived Mesenchymal Stem cells from healthy donors for the treatment of perianal fistulas in patients presenting CD.

Primary objective: To assess the safety (incidence of treatment emergent adverse-events) of TH-SC01

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Crohn's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TH-SC01

TH-SC01 24 mL suspension of 120 million cells as a perilesional injection, once on Day 0.

Group Type EXPERIMENTAL

TH-SC01

Intervention Type DRUG

Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

TH-SC01

Allogeneic Umbilical Cord-derived Mesenchymal Stem cells perilesional injection. Human TH-SC01 cell injection (human umbilical cord mesenchymal stem cells for injection, 5 million cells / ml, 6.0-10.0ml / bottle)

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 1\. Signed Informed Consent；
* 2\. According to the Diagnostic Criterion for Crohn's Disease in China's 《Consensus on the Diagnosis and Treatment of Inflammatory Bowel Disease》 (2018, Beijing), Crohn's disease was diagnosed at least 6 months before the screening period；
* 3\. Crohn's disease activity index (CDAI) score of 220 or less is defined as inactive or mildly active luminal Crohn's disease；
* 4\. Through clinical evaluation, MRI evaluation for anal fistula patients；
* 5\. Age 18 \~ 70, male or female；
* 6\. The serum or urine pregnancy test of a woman of reproductive age must be negative. Both men and women must agree to use a contraceptive method；
* 7\. According to the history and related examination, the general health condition is good；
* 8\. The eligible patients must at least meet one of the following conditions: patients who have failed to respond to any conventional treatment, such as conventional antibiotic therapy, immunomodulatory drug therapy, anti-tumor necrosis factor (TNF) α monoclonal antibody therapy, and 5-aminosalicylic acid

Exclusion Criteria

* 1\. CDAI \> 220, or due to Crohn's disease activity, treatment needs to be upgraded immediately；
* 2\. Patients with abdominal and pelvic abscess or fistula diameter more than 2 cm；
* 3\. Patients with rectal and/or anal stenosis and/or active proctitis (due to limited surgical procedures)；
* 4\. The number of internal and / or external openings of anal fistula was more than 2 and 3 respectively;
* 5\. Patients who received steroid therapy within the first 4 weeks were screened；
* 6\. Abnormal laboratory test results： Liver function: total bilirubin ≥1.5 times the upper limit of normal value, aspartate aminotransferase (AST) or alanine aminotransferase (ALT)≥2.5 times the upper limit of normal value; Renal function: Creatinine clearance below 60mL/min or 1.5 times the upper normal limit of serum creatinine (measured value or calculated by the Cockcroft-Gault formula)；
* 7.Patients with malignancy or a history of malignancy, including fistula cancer of any type；
* 8\. Patients with severe, progressive, uncontrollable diseases of the liver, blood, gastrointestinal (except Crohn's disease), endocrine, lung, heart, neurological, psychiatric, or brain；
* 9\. HIV, syphilis antibody positive, HCV / HBV positive, tuberculosis in the infectious period, etc;
* 10\. Patients who are allergic to human serum albumin, human platelet lysates, anesthetic agents or contrast agents；
* 11\. Patients with contraindications to MRI scanning；
* 12\. Pregnant or lactating women and subjects who cannot commit to using effective contraceptives during the trial and for 6 months after the end of the trial；
* 13\. Patients who have undergone major surgery or severe trauma in the past six months；
* 14\. Patients who had received any study drug within a certain period of time prior to screening；
* 15.Patients deemed ineligible to participate in this clinical trial by the investigator

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No